# An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

> **NCT03338790** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 292 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** nivolumab
- **DRUG:** docetaxel
- **DRUG:** enzalutamide
- **DRUG:** rucaparib
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT03338790
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-19
- **Primary completion:** 2021-01-13
- **Final completion:** 2025-01-10
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03338790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03338790, "An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03338790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*